Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of prostaglandin I2 binding sites in thyroid cancer.

I Virgolini1, M Hermann, H Sinzinger

  • 12nd Department of Nuclear Medicine, Ludwig Boltzmann Institute for Nuclear Medicine, University of Vienna, Austria.

British Journal of Cancer
|November 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished.

Thrombosis research·1995
Same author

Passive smoking and cardiovascular risk.

Archives of internal medicine·1995
Same author

Gamma irradiation is not a novel approach to inhibit neointimal hyperplasia after arterial injury.

Stroke·1995
Same author

Arterial wall rather than platelets is responsible for diminished thrombogenicity during isradipine therapy.

Journal of cardiovascular pharmacology·1995
Same author

Evidence for lipid regression in humans in vivo performed by 123iodine-low-density lipoprotein scintiscanning.

Annals of the New York Academy of Sciences·1995
Same author

[1995 consensus guidelines for cholesterol. Society of Physicians in Vienna].

Wiener klinische Wochenschrift·1995
Same journal

The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.

British journal of cancer·2026
Same journal

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same journal

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.

British journal of cancer·2026
Same journal

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

British journal of cancer·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
See all related articles

This study characterizes prostaglandin I2 (prostacyclin, PGI2) binding sites in thyroid tissues. Prostacyclin receptor binding is altered in thyroid nodules and cancers, suggesting a role in thyroid pathophysiology.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Prostaglandin I2 (prostacyclin, PGI2) plays a role in various physiological processes.
  • Understanding PGI2 binding site properties in thyroid tissue is crucial for elucidating its function.

Purpose of the Study:

  • To characterize specific prostaglandin I2 (prostacyclin, PGI2) binding sites in normal thyroid tissue.
  • To investigate alterations in PGI2 binding site characteristics in benign thyroid nodules and thyroid cancers.

Main Methods:

  • Thyroid tissue samples from patients with solitary thyroid nodules were used.
  • Membrane preparations were analyzed using [3H]iloprost, a stable PGI2-analogue, as a radioligand.
  • Saturation binding experiments and Scatchard analysis were performed to determine binding capacities (Bmax) and affinities (Kd).

Related Experiment Videos

Main Results:

  • Normal thyroid tissue exhibited heterogeneous [3H]iloprost binding sites with high and low affinity.
  • Benign thyroid adenomas showed significantly lower binding capacities compared to normal tissue.
  • Thyroid cancers displayed a selective loss of low-affinity sites and a significant reduction in high-affinity sites, with further diminution in less differentiated cancers.

Conclusions:

  • Prostacyclin (PGI2) receptor binding characteristics differ between normal thyroid tissue, benign adenomas, and malignant thyroid cancers.
  • The observed alterations in PGI2 binding sites suggest their involvement in thyroid nodule development and cancer progression.